GHD7 Antibody

What is GHD7 and what are its key functional domains?

GHD7 (Grain number, plant height, and heading date 7) is a transcription factor primarily involved in regulating flowering time under long day conditions. It functions as a flowering repressor by negatively regulating the expression of HD3A and acting downstream of phytochrome B to repress EHD1, an activator of flowering promoter genes .

The protein contains several important functional domains:

• A CCT (CONSTANS, CO-like, and TOC1) domain at the C-terminal region critical for transcriptional regulation

• Two potential protein ubiquitination sites: lysine residues at positions 165 and 231

• The 231st lysine residue within the CCT domain is particularly important for sucrose-dependent degradation

GHD7 appears to be a component of the circadian clock system, with its expression controlled by circadian rhythm in a coordinated sequence with other PRR (PSEUDO-RESPONSE REGULATOR) family members .

What types of GHD7 antibodies are available for research applications?

Based on current research literature, several types of GHD7 antibodies are available for research:

• Polyclonal antibodies: Rabbit polyclonal antibodies with high reactivity against GHD7 (particularly from Oryza sativa)

• Domain-specific antibodies: Antibodies targeting specific regions of GHD7, useful for studying protein interactions and modifications

• Anti-GHD7 antibodies for developmental studies: Used to examine GHD7 protein levels across different developmental stages

These antibodies have been validated for applications including Western blotting, ELISA, immunoprecipitation, and protein interaction studies .

How can I validate the specificity of a GHD7 antibody for my research?

Validating GHD7 antibody specificity requires a multi-faceted approach:

• Western blot analysis:

  • Use protein extracts from wild-type plants and ghd7 mutants or knockdowns

  • Confirm detection of a band at the expected molecular weight (approximately 80kDa)

  • Verify absence of the band in null mutants or reduced signal in knockdown lines

• Immunoprecipitation validation:

  • Perform immunoprecipitation followed by mass spectrometry to confirm protein identity

  • Use tagged versions of GHD7 (e.g., GHD7-HA) for co-immunoprecipitation assays with known interactors like IPI1

• Expression pattern analysis:

  • Compare antibody detection patterns with known transcriptional profiles of GHD7

  • Examine protein levels at multiple developmental stages

  • Confirm nuclear localization, as GHD7 functions as a transcription factor

• Cross-reactivity testing:

  • Test antibody against closely related proteins (particularly other CCT domain-containing proteins)

  • Include appropriate positive and negative controls in all experiments

What are the optimal conditions for using GHD7 antibodies in Western blot applications?

For optimal Western blot detection of GHD7 protein:

• Sample preparation:

  • Extract nuclear proteins from appropriate plant tissues (GHD7 is primarily localized in the nucleus)

  • Include protease inhibitors to prevent degradation

  • Consider adding phosphatase inhibitors if studying phosphorylation states

• Recommended dilutions and conditions:

  • For rabbit polyclonal GHD7 antibodies, use dilutions in the range of 1:500 - 1:2000 for Western blot applications

  • Block membranes with 5% non-fat dry milk or BSA in TBST

  • Incubate primary antibody overnight at 4°C for optimal binding

• Detection strategies:

  • Use appropriate secondary antibodies conjugated to HRP, fluorescent tags, or other detection systems

  • Include positive controls (e.g., recombinant GHD7 protein) and negative controls

  • For weak signals, consider enhanced chemiluminescence detection systems

• Troubleshooting considerations:

  • If multiple bands appear, optimize blocking conditions or try more specific antibodies

  • For tissues with low GHD7 expression, consider immunoprecipitation before Western blotting

  • When comparing expression levels, ensure equal loading with appropriate controls

How can I use GHD7 antibodies to study developmental expression patterns?

To effectively study GHD7 developmental expression patterns:

• Temporal sampling strategy:

  • Collect samples at regular intervals throughout development (e.g., every 2 weeks)

  • Include multiple time points during the day to account for diurnal expression patterns

  • Sample at equivalent developmental stages when comparing different genotypes

• Tissue-specific analysis:

  • Collect multiple tissue types (leaves, stems, flowers, etc.)

  • Use nuclear extraction protocols for optimal GHD7 recovery

  • Compare protein levels across tissues to identify spatial regulation patterns

• Quantification methods:

  • Use densitometry analysis of Western blots with appropriate normalization

  • Include loading controls (e.g., histone proteins for nuclear extracts)

  • Consider parallel qRT-PCR to compare transcript and protein levels

• Experimental design for developmental studies:

  • Include multiple biological replicates

  • Grow plants under controlled conditions with standardized photoperiods

  • Document environmental parameters that might affect GHD7 expression

What approaches can I use to study GHD7 interactions with other proteins?

To investigate GHD7 protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use anti-GHD7 antibodies to pull down protein complexes

  • Analyze co-precipitated proteins by Western blotting or mass spectrometry

  • Example: Co-IP assays with GHD7-HA and IPI1-Myc confirmed their interaction

• Bimolecular Fluorescence Complementation (BiFC):

  • Create fusion constructs of GHD7 with the N-terminus of YFP (GHD7-nYFP)

  • Fuse potential partners with the C-terminus of YFP (Partner-cYFP)

  • Co-transfer to protoplasts and observe fluorescence signal location

  • Example: GHD7-nYFP and IPI1-cYFP showed yellow fluorescence in the nucleus, confirming interaction

• Yeast Two-Hybrid screening:

  • Use full-length GHD7 or specific domains as bait

  • Screen against cDNA libraries to identify novel interactors

  • Follow with directed one-to-one binding assays for confirmation

  • Example: Y2H screening with GHD7 181-257 identified E3 ligase IPI1 as an interaction partner

• Pull-down assays with recombinant proteins:

  • Express and purify recombinant GHD7 or domains of interest

  • Perform in vitro binding assays with candidate interacting proteins

  • Use appropriate tags for purification and detection

How can I investigate post-translational modifications of GHD7 using antibodies?

Studying post-translational modifications (PTMs) of GHD7 requires specialized approaches:

• Ubiquitination analysis:

  • Immunoprecipitate GHD7 and probe with anti-ubiquitin antibodies

  • Use linkage-specific antibodies to distinguish between K48 and K63 polyubiquitin chains

  • Example: K48-linked chains were added to GHD7 in mannitol solution, while K63-linked chains appeared in sucrose solution

• Phosphorylation studies:

  • Use phospho-specific antibodies if available, or general phospho-detection methods

  • Combine with phosphatase treatments as controls

  • Perform mass spectrometry analysis of immunoprecipitated GHD7 to identify phosphorylation sites

• Mutation-based approaches:

  • Generate site-specific mutants (e.g., K231R) that cannot be modified at key sites

  • Compare stability and function of wild-type and mutant proteins

  • Example: The GHD7 K231R variant did not undergo sucrose-induced degradation

• Domain mapping experiments:

  • Create truncated versions of GHD7 to identify regions susceptible to specific modifications

  • Express constructs in protoplasts and analyze modification patterns

  • Example: Analysis of various truncated forms (GHD7 1-230, GHD7 1-163, GHD7 114-257, etc.) identified the C-terminal region as sensitive to sucrose-induced degradation

• PTM enzyme identification:

  • Use co-immunoprecipitation to identify enzymes that modify GHD7

  • Test direct interactions through in vitro assays

  • Example: The E3 ligase IPI1 was identified as binding to GHD7's C-terminal region

What experimental design should I use to study GHD7 degradation pathways?

To effectively investigate GHD7 degradation mechanisms:

• Protein stability assays:

  • Conduct cycloheximide chase experiments to track protein half-life

  • Compare degradation rates under different conditions (e.g., sucrose vs. mannitol)

  • Include proteasome inhibitors (e.g., MG132) to block degradation

  • Monitor protein levels by Western blotting at multiple time points

• Ubiquitination analysis:

  • Design experiments to detect different types of ubiquitin chains

  • Compare K48-linked vs. K63-linked polyubiquitination under various conditions

  • Use mutant forms of ubiquitin (K48R, K63R) to block specific chain formation

• Structure-function analysis:

  • Generate lysine-to-arginine mutations at potential ubiquitination sites

  • Create truncated forms to identify regions necessary for degradation

  • Example experimental design:

• E3 ligase identification:

  • Use yeast two-hybrid screening to identify potential E3 ligases

  • Map interaction domains through directed experiments with protein fragments

  • Example: IPI1 97-455 fragment containing the C-terminal region bound to GHD7, while IPI1 1-96 did not

How do genetic interactions between GHD7 and other flowering regulators affect experimental design?

The complex genetic interactions of GHD7 necessitate careful experimental design:

• Genetic background considerations:

  • Choose appropriate genetic backgrounds where interacting genes are well-characterized

  • Use near-isogenic lines differing only in alleles of interest

  • Example: Combinations of Ghd7, Ghd7.1, Ghd8, and Hd1 in ZS97 background showed stronger photoperiod sensitivity under NLD conditions

• Factorial experimental design:

  • Test all possible combinations of functional and non-functional alleles

  • Document interactions that may cause extreme phenotypes

  • Example: Ghd7 and Ghd8 in the ZS97 background with functional Hd1 caused non-heading under NLD conditions

• Environmental control:

  • Test phenotypes under multiple photoperiod conditions

  • Include natural and controlled environment experiments

  • Document all environmental parameters throughout experiments

• Molecular characterization approaches:

  • Monitor expression levels of all interacting genes simultaneously

  • Investigate whether interactions occur at protein-protein or transcriptional levels

  • Example: Ghd7.1 shares the CCT domain with Hd1 and Ghd7 and forms heterotrimers with Ghd8 and NF-YCs

• Transgenic approaches:

  • Create overexpression and knockdown lines for each gene individually and in combination

  • Example transgenic effects:

How can I resolve contradictory results in GHD7 protein expression studies?

When facing conflicting results in GHD7 studies, implement these methodological approaches:

• Standardize experimental conditions:

  • Control environmental factors, particularly photoperiod and temperature

  • Sample at consistent times due to GHD7's circadian expression

  • Use plants at equivalent developmental stages

• Genetic background assessment:

  • Document and account for genetic background differences

  • Include appropriate controls from different backgrounds

  • Consider performing haplotype analysis of GHD7 to understand allelic variation effects

• Multi-level analysis protocol:

  • Compare transcript data with protein expression data

  • Examine both protein abundance and post-translational modifications

  • Collect samples at multiple timepoints to capture temporal dynamics

• Antibody validation approach:

  • Use multiple antibodies targeting different GHD7 epitopes

  • Include appropriate positive and negative controls

  • For transgenic experiments, demonstrate cosegregation between transgene and phenotype

• Hormone and metabolite considerations:

  • Test effects of relevant hormones (e.g., GA) and metabolites (e.g., sucrose)

  • Measure endogenous hormone levels in experimental tissues

  • Example: GA1 level in NIL-J was approximately 84.6% (0.69 ng/g) of that in NIL-C (0.81 ng/g)

What are common challenges when working with GHD7 antibodies and how can I overcome them?

Common challenges and solutions when working with GHD7 antibodies include:

• Low signal intensity:

  • Optimize antibody concentration through titration experiments

  • Use signal enhancement systems (e.g., enhanced chemiluminescence)

  • Consider immunoprecipitation to concentrate the protein before detection

  • Ensure the protein extraction method preserves nuclear proteins

• Background or non-specific binding:

  • Optimize blocking conditions (try different blocking agents)

  • Increase washing steps and duration

  • Pre-absorb antibody with non-specific proteins

  • Use more specific secondary antibodies

• Protein degradation during extraction:

  • Include multiple protease inhibitors in extraction buffers

  • Keep samples cold throughout processing

  • Consider using proteasome inhibitors like MG132 if studying ubiquitination

  • Process samples quickly to minimize degradation

• Diurnal variation effects:

  • Collect samples at consistent times of day

  • Include multiple timepoints within a day if possible

  • Document and control light conditions during experiments

• Cross-reactivity with related proteins:

  • Use immunoprecipitation followed by mass spectrometry to confirm targets

  • Include appropriate knockout/knockdown controls

  • Consider using epitope-tagged versions of GHD7 for greater specificity

How can I optimize immunoprecipitation protocols for GHD7 studies?

For effective GHD7 immunoprecipitation:

• Buffer optimization:

  • Use buffers that maintain protein-protein interactions (e.g., HEPES-based buffers)

  • Include appropriate salt concentration (typically 150mM NaCl)

  • Add detergents at concentrations that solubilize membranes without disrupting interactions

  • Example buffer: 10mM HEPES, pH 7.4, 150mM NaCl, 3mM EDTA, 0.005% surfactant P20

• Antibody selection and coupling:

  • Use high-affinity antibodies specifically validated for immunoprecipitation

  • Consider coupling antibodies to solid supports (e.g., Protein A/G beads or magnetic beads)

  • For co-IP studies, epitope-tagged versions (GHD7-HA) can provide better specificity

• Pre-clearing and controls:

  • Pre-clear lysates with beads alone to reduce non-specific binding

  • Include negative controls (non-specific IgG or immunoprecipitation from knockout lines)

  • Use stringent washing conditions to remove non-specifically bound proteins

• Elution and analysis strategies:

  • Elute under native conditions if studying protein interactions

  • For identification of binding partners, elute directly into SDS sample buffer

  • Consider on-bead digestion for mass spectrometry applications

  • For ubiquitination studies, include deubiquitinase inhibitors throughout the procedure

What emerging techniques might enhance GHD7 antibody applications in research?

Several emerging techniques show promise for advancing GHD7 research:

• Proximity labeling approaches:

  • BioID or TurboID fusion proteins to identify proteins in close proximity to GHD7

  • APEX2-based methods for temporally controlled labeling

  • These approaches could identify transient or weak interactions missed by conventional methods

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize GHD7 subcellular localization with greater precision

  • Förster resonance energy transfer (FRET) to study dynamic protein interactions

  • Live-cell imaging with tagged GHD7 to track protein dynamics in real-time

• Cryo-electron microscopy:

  • Structural analysis of GHD7 complexes with interacting proteins

  • Understanding the structural basis of GHD7 interactions with DNA and other proteins

  • Insights into how post-translational modifications alter protein conformation

• Single-cell approaches:

  • Single-cell proteomics to study cell-specific GHD7 expression patterns

  • Correlation of GHD7 protein levels with transcriptomic profiles at single-cell resolution

  • Understanding cell-to-cell variability in GHD7 regulation

• Genome editing technologies:

  • CRISPR-Cas9 to generate precise mutations in endogenous GHD7

  • Homology-directed repair to introduce epitope tags into the endogenous locus

  • Base editing for introducing specific amino acid changes without double-strand breaks

How might understanding GHD7 function contribute to broader research areas?

Understanding GHD7 function has implications for multiple research areas:

• Crop improvement applications:

  • Manipulation of GHD7 for optimizing flowering time in different environments

  • Modulation of GHD7 activity to enhance grain yield potential

  • Development of varieties with improved adaptability to changing climatic conditions

  • Example: Transgenic plants overexpressing GHD7 showed increased grain number (267.5 ± 21.7 vs. 166.5 ± 14.0 in wild type)

• Signaling pathway integration:

  • Understanding how GHD7 integrates environmental signals with developmental timing

  • Elucidating links between sugar signaling and flowering through GHD7 degradation

  • Uncovering connections between circadian rhythm and developmental transitions

• Evolutionary biology insights:

  • Comparative studies of GHD7 function across plant species

  • Understanding how GHD7-like proteins evolved specialized functions

  • Investigating how genetic variation in GHD7 contributes to environmental adaptation

• Systems biology approaches:

  • Integration of GHD7 into broader regulatory networks

  • Mathematical modeling of GHD7 dynamics in response to environmental cues

  • Predicting phenotypic outcomes based on GHD7 status and environmental conditions